Related references
Note: Only part of the references are listed.Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A. Meta-Analysis
Vishal Ranpura et al.
AMERICAN JOURNAL OF HYPERTENSION (2010)
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
Hassane Izzedine et al.
EUROPEAN JOURNAL OF CANCER (2010)
Hypertension as a surrogate marker for the activity of anti-VEGF agents
O. Mir et al.
ANNALS OF ONCOLOGY (2009)
Management of hypertension in angiogenesis inhibitor-treated patients
H. Izzedine et al.
ANNALS OF ONCOLOGY (2009)
Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors
Marlies H. G. Langenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
Frank A. Scappaticci et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis
Xiaolei Zhu et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway
Shin-ichiro Miura et al.
HYPERTENSION RESEARCH (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
A Trotti et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Ambulatory blood pressure measurement is indispensable to good clinical practice
E O'Brien
JOURNAL OF HYPERTENSION (2003)
Share Paper
